Arbutus Biopharma Corporation
ABUS
$4.46
-$0.44-8.98%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 508.79% | 12.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 508.79% | 12.07% | |||
| Cost of Revenue | -95.83% | 1.69% | |||
| Gross Profit | 244.06% | 0.57% | |||
| SG&A Expenses | -42.94% | -30.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -40.33% | -14.22% | |||
| Operating Income | 114.68% | 16.86% | |||
| Income Before Tax | 110.29% | -95.71% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 110.29% | -95.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 110.29% | -95.71% | |||
| EBIT | 114.68% | 16.86% | |||
| EBITDA | 115.15% | 17.20% | |||
| EPS Basic | 110.26% | -94.55% | |||
| Normalized Basic EPS | 124.74% | 17.45% | |||
| EPS Diluted | 107.78% | -85.57% | |||
| Normalized Diluted EPS | 124.74% | 17.45% | |||
| Average Basic Shares Outstanding | 0.44% | 0.53% | |||
| Average Diluted Shares Outstanding | 0.89% | 0.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||